Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
QNTM moved a median of 0.00% 30 minutes after news, and -0.31% by the close. How QNTM actually reacts to news — the realized, point-in-time move the market made, measured across 400 labeled events over the last three years with zero look-ahead.
QNTM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.00% | 38% | 374 |
| 30-min | 0.00% | 50% | 393 |
| 60-min | 0.00% | 50% | 397 |
| to close | -0.31% | 47% | 397 |
| Middle 50% of QNTM reactions | -2.25% to +2.70% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 400 |
Half of all Quantum Biopharma Ltd. - Class B Subordinate Voting Shares news events land between -2.25% and +2.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when QNTM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QNTM's baseline. Nothing else.
Recent QNTM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Quantum Biopharma Ltd. For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | +0.48% | +0.32% | |
| Form 6-K Quantum Biopharma Ltd. For: Oct 06 | SEC filing · Form 6-K | SEC EDGAR | -1.20% | -7.49% | |
| Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | Press release | GlobeNewswire | -1.20% | -7.49% | |
| IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. | Press release | GlobeNewswire | -4.30% | -3.23% | |
| Form 6-K Quantum Biopharma Ltd. For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +0.24% | +0.00% | |
| Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO | Press release | GlobeNewswire | +0.24% | +0.00% | |
| Form 6-K Quantum Biopharma Ltd. For: Sep 17 | SEC filing · Form 6-K | SEC EDGAR | +1.79% | +2.48% | |
| Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | Press release | GlobeNewswire | +1.79% | +2.48% | |
| Form 6-K Quantum Biopharma Ltd. For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | -0.73% | +0.88% | |
| Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto | Press release | GlobeNewswire | -0.73% | +0.88% | |
| NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research | Press release | GlobeNewswire | +0.72% | +7.45% | |
| Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials | Press release | GlobeNewswire | +0.90% | -3.61% | |
| Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market | Press release | GlobeNewswire | -0.00% | -7.06% | |
| Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment | Press release | GlobeNewswire | +3.29% | +7.19% | |
| A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach | Press release | GlobeNewswire | +0.76% | +0.30% | |
| Form 6-K/A Quantum Biopharma Ltd. For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | — | -0.60% | |
| Form 6-K Quantum Biopharma Ltd. For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | +0.98% | +0.33% | |
| Form 6-K Quantum Biopharma Ltd. For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | +1.65% | +13.77% | |
| Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial | Press release | GlobeNewswire | +1.65% | +13.77% | |
| Form 6-K Quantum Biopharma Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +1.65% | +13.77% | |
| Form 6-K/A Quantum Biopharma Ltd. For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | -0.31% | |
| Form 6-K Quantum Biopharma Ltd. For: Aug 10 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: | Press release | GlobeNewswire | — | — | |
| NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis | Press release | GlobeNewswire | +0.13% | -3.31% | |
| Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy | Press release | GlobeNewswire | -1.26% | -1.26% | |
| The Quest to Repair What Multiple Sclerosis Takes Away | Press release | GlobeNewswire | +1.70% | +2.09% | |
| Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach | Press release | GlobeNewswire | +0.57% | +10.00% | |
| Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis | Press release | GlobeNewswire | -2.16% | -1.08% | |
| Form 6-K Quantum Biopharma Ltd. For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | -0.12% | +0.79% | |
| Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns | Press release | GlobeNewswire | -0.12% | +0.79% | |
| Form 6-K Quantum Biopharma Ltd. For: May 18 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | -15.84% | |
| Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital | Press release | GlobeNewswire | -0.07% | -15.84% | |
| Form 6-K Quantum Biopharma Ltd. For: May 07 | SEC filing · Form 6-K | SEC EDGAR | -1.90% | -4.57% | |
| Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 | Press release | GlobeNewswire | -1.90% | -4.57% | |
| Form 6-K Quantum Biopharma Ltd. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -1.90% | -4.57% | |
| Form 6-K Quantum Biopharma Ltd. For: Apr 22 | SEC filing · Form 6-K | SEC EDGAR | +2.91% | -7.20% | |
| Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant | Press release | GlobeNewswire | +5.38% | -5.10% | |
| Form 6-K Quantum Biopharma Ltd. For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | -3.26% | -10.56% | |
| Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied | Press release | GlobeNewswire | -3.26% | -10.56% | |
| Form 6-K Quantum Biopharma Ltd. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | +6.46% | -15.03% | |
| Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis | Press release | GlobeNewswire | +6.46% | -15.03% | |
| Form 6-K Quantum Biopharma Ltd. For: Mar 30 | SEC filing · Form 6-K | SEC EDGAR | +4.55% | -15.25% | |
| Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis | Press release | GlobeNewswire | +4.55% | -15.25% | |
| Form 6-K Quantum Biopharma Ltd. For: Mar 27 | SEC filing · Form 6-K | SEC EDGAR | +9.12% | +35.90% | |
| Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status | Press release | GlobeNewswire | +9.12% | +35.90% | |
| Form 20-F Quantum Biopharma Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +9.12% | +35.90% | |
| Form 6-K Quantum Biopharma Ltd. For: Mar 26 | SEC filing · Form 6-K | SEC EDGAR | -1.91% | -8.81% | |
| Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis | Press release | GlobeNewswire | -1.91% | -8.81% | |
| Form 6-K Quantum Biopharma Ltd. For: Mar 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +40.27% | |
| Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd | Press release | GlobeNewswire | +0.00% | +40.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QNTM section they belong to.
Where else QNTM is measured.
QNTM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares's median reaction calculated?
Every labeled QNTM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 400 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of QNTM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QNTM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.